Clinical Trials Logo

Filter by:
NCT ID: NCT06087484 Not yet recruiting - Emotional Distress Clinical Trials

The Effect of Mindfulness Intervention for Emotional Distress of Insomnia People

Start date: October 16, 2023
Phase: N/A
Study type: Interventional

Exploring the Effectiveness of a mindfulness intervention for Insomniacs with Emotional Distress Comparing the intervention effects of two mindfulness interventions

NCT ID: NCT06087068 Recruiting - Surgery Clinical Trials

Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma

Start date: August 1, 2022
Phase: Phase 2
Study type: Interventional

Papillary thyroid carcinoma (PTC) is the most common thyroid cancer and has a good prognosis.According to the 2015 American thyroid association (ATA) guidelines, no gross extrathyroidal extension and the number of pathological lymph node micrometastases (<0.2cm) ≤5 were defined as the low recurrence risk group. After total thyroidectomy and radioiodine treatment, the probability of disease-free status (irritant Tg<1ng/ml, no evidence of other disease recurrence) is about 78%-91%, and the probability of structural recurrence is about 1%-10%. In recent years, due to the further understanding of PTC, surgeons tend to become more conservative in treatment, such as active observation or reducing the extent of surgery. The indication for lobectomy has been extended to tumors <4cm without extrathyroidal extension and clinical lymph node metastasis. For patients treated with lobectomy, current guidelines recommend that Thyroid Stimulating Hormone (TSH) be controlled at 0.5-2 mU/L, but evidence on the prognostic benefits of this TSH inhibition range is lacking.In recent years, a number of studies have suggested that if postoperative TSH in low-risk patients after lobectomy is acceptable within the reference range, it means that a considerable number of patients have a high probability of not receiving thyroxine replacement therapy after surgery, which can significantly improve their quality of life.A previous retrospective study from our institute showed no significant association between TSH levels after lobectomy and prognosis.The aim of this study was to evaluate the benefits and risks of postoperative TSH levels within the reference range (0.4-5 mU/L) in patients with low-risk papillary thyroid cancer who underwent lobectomy.In order to improve the effect of longer recurrence and death time of PTC, the investigators also performed postoperative thyroglobulin and its antibody for short-term treatment response evaluation.

NCT ID: NCT06087055 Completed - Healthy Participant Clinical Trials

Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy Participants

Start date: May 12, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to estimate the effect of a strong inhibitor of CYP3A4 (itraconazole) on the pharmacokinetics (PK) of GST-HG171/ritonavir in healthy participants.

NCT ID: NCT06087003 Completed - Clinical trials for Kidney Transplant Rejection

Pediatric Induction Therapy in Kidney Transplantation

PINK
Start date: March 3, 2013
Phase:
Study type: Observational

The goal of this observational study is to compare the efficacy of two most commonly used induction therapy for the prevention of acute rejection (AR) after renal transplantation in children. The main question it aims to answer is: Is basiliximab (anti-CD25 monoclonal antibody) induction therapy effective and safe in preventing AR after kidney transplantation in children compared with anti-thymoglobulin polyclonal antibodies induction therapy? The transplant and follow-up data of participants will be retrospectively collected. Researchers will compare the rate of AR to see if basiliximab (anti-CD25 monoclonal antibody) induction therapy is a better option for certain pediatric kidney transplant recipients.

NCT ID: NCT06086912 Completed - Type 2 Diabetes Clinical Trials

A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites

Start date: November 7, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the bioavailability and safety of HR17031 injection in healthy subjects at different sites.

NCT ID: NCT06086457 Recruiting - Clinical trials for Esophageal Neoplasms

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Start date: February 4, 2024
Phase: Phase 3
Study type: Interventional

The treatment efficacy for stage IVb esophageal cancer has been improved through chemotherapy combined with immunotherapy recently. On this basis, the investigators intend to conduct a prospective, multicenter phase III clinical trial to assess whether radiotherapy with concurrent chemotherapy and immunotherapy could further improve the survival of patients with metastatic esophageal cancer. Accompanied tissue samples, blood samples and urine samples will be analyzed by molecular biological detection (Including Whole Exome Sequencing and proteomics) to explore potential biomarkers for predicting outcomes, efficacy and toxicity.

NCT ID: NCT06086327 Recruiting - Thymoma Clinical Trials

Application of 68Ga-Pentixafor PET/CT for Thymoma

Start date: June 22, 2023
Phase: Early Phase 1
Study type: Interventional

Chemokine receptor CXCR4 was expressed in T cells and CXCR4-targeting molecular imaging- 68Ga-Pentixafor PET/CT could be a promising technique to evaluate the extent of thymoma with higher accuracy. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, distinguish evaluation for thymoma.

NCT ID: NCT06086197 Recruiting - Clinical trials for Diffuse Large B-cell Lymphoma Recurrent

A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

Start date: January 1, 2023
Phase: Phase 2
Study type: Interventional

As the most common subtype of lymphoma, diffuse large B-cell lymphoma (DLBCL) is an aggressive but potentially curable malignancy. However, patients with early relapse (relapse within 12 months since diagnosis or the end of first-line treatment, ER) or primary refractory had an even worse prognosis. Thus, the investigators plan to evaluate the efficacy and safety of anlotinib combined with rituximab, gemcitabine, oxaliplatin (A-RGEMOX) in the treatment of early relapsed/refractory diffuse large B-cell lymphoma.

NCT ID: NCT06085859 Recruiting - Hypoxemia Clinical Trials

Anesthesia Endoscope Mask is Applied to Sedation Upper Gastrointestinal Endoscopic Diagnosis and Treatment

Start date: October 18, 2023
Phase: N/A
Study type: Interventional

To investigate the efficacy and safety of new-type mask compared with nasal tube oxygen delivery in patients undergoing sedation of upper gastrointestinal endoscopy

NCT ID: NCT06085768 Recruiting - Clinical trials for Virtual Reality Exposure Therapy

A Preliminary Study on the Intervention Effect of Virtual Reality Exposure Therapy on Fear of Flying

Start date: June 19, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore the efficacy of VR exposure intervention in alleviating fear of flying through a randomized controlled study.